Pancreatic Cancer Research

ResearcherUniversitat Autònoma de BarcelonaNo recent work listed

Daniel Massó-Vallés

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4231-0456; OpenAlex author ID A5090976422. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper

Papers 3

  1. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. First author DOI 10.18632/oncotarget.24648↗
  2. Pancreatic cancer heterogeneity and response to Mek inhibition. Co-author DOI 10.1038/onc.2017.174↗
  3. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-14-2852↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laura Soucek · 3 shared papers, 2015–2018 · strength 0.18
  2. Toni Jauset Gonzalez · 2 shared papers, 2015–2018 · strength 0.12
  3. Kim Pedersen · 2 shared papers, 2015–2017 · strength 0.10
  4. Joaquı́n Arribas · 2 shared papers, 2015–2017 · strength 0.10
  5. Faiz Bilal Espejo · 1 shared paper, 2017 · strength 0.06
  6. Irit Sagi · 1 shared paper, 2017 · strength 0.06
  7. Vishnu Mohan · 1 shared paper, 2017 · strength 0.06
  8. Josep M. Tabernero · 1 shared paper, 2017 · strength 0.06
  9. Ana P. Vivancos · 1 shared paper, 2017 · strength 0.06
  10. Teresa Mercade Macarulla · 1 shared paper, 2017 · strength 0.06
  11. Nicole M. Sodir · 1 shared paper, 2015 · strength 0.05
  12. Gérard I. Evan · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.